HOFFMANN-LA ROCHE INC.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology MATTERS Rank in Class
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 581 18
 
 
C07D HETEROCYCLIC COMPOUNDS 485 10
 
 
C07K PEPTIDES 275 8
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 93 114
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 69 98
 
 
C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 60 78
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 55 47
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 44 12
 
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 35 60
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 29 96
  • No Technologies to Display

Top Patents (by citation)

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2018/0072,725 NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION Nov 20, 17 Mar 15, 18 [C07D]
2018/0072,804 ANTI-TIM3 ANTIBODIES AND METHODS OF USE Apr 21, 17 Mar 15, 18 [C07K]
2018/0073,088 NOVEL HIGH-THROUGHPUT METHOD FOR QUANTIFICATION OF HBV CCCDNA FROM CELL LYSTATE BY REAL-TIME PCR Jun 29, 17 Mar 15, 18 [C12Q]
2018/0064,808 COMBINATION THERAPY OF BISPECIFIC ANTIBODIES SPECIFIC FOR FAP AND DR5 AND CHEMOTHERAPEUTIC AGENTS Apr 07, 17 Mar 08, 18 [A61K, C07K]
2018/0057,526 NEW DIFLUOROKETAMIDE DERIVATIVES Nov 07, 17 Mar 01, 18 [C07K]
2018/0051,077 COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1 Oct 02, 17 Feb 22, 18 [A61K, C07K]
2018/0042,853 PHARMACEUTICAL FORMULATION COMPRISING SEMBRAGILINE Sep 26, 17 Feb 15, 18 [A61K]
2018/0029,978 PROCESS FOR MAKING LYSINE-GLUTAMIC ACID DIPEPTIDE DERIVATIVES Oct 11, 17 Feb 01, 18 [C07C]
2018/0029,996 BICYCLIC QUINAZOLINONE DERIVATIVES Oct 10, 17 Feb 01, 18 [C07D]
2018/0027,639 METHOD AND APPARATUS FOR ELECTROSTATICALLY DISCHARGING A PRIMARY PACKAGING CONTAINER MADE OF PLASTICS Sep 29, 17 Jan 25, 18 [H05F]

View all publication…

  • No Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9920049 Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection Nov 11, 16 Mar 20, 18 [C07D]
9920072 BACE1 inhibitors Oct 30, 15 Mar 20, 18 [C07D]
9920970 Flexible cryogenic container system Jul 14, 11 Mar 20, 18 [A01N, F25D]
9914776 Bispecific T cell activating antigen binding molecules Aug 03, 15 Mar 13, 18 [A61K, C07K]
9915650 Method of detection of cAMP and cGMP via a fluorophore and dequencher complex Dec 13, 07 Mar 13, 18 [C12Q, G01N]
9909178 Dalcetrapib for therapeutic use Sep 23, 15 Mar 06, 18 [A01N, C12Q, A61K]
9902701 Pyridazones and triazinones for treatment and prophylaxis of hepatitis B virus infection Feb 14, 17 Feb 27, 18 [C07D, A61K]
9896438 2,2,2-trifluoroethyl-thiadiazines Aug 12, 15 Feb 20, 18 [C07D]
9890124 Benzazepine sulfonamide compounds Jun 14, 17 Feb 13, 18 [C07D, A61P, A61K]
9890155 Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection Feb 11, 16 Feb 13, 18 [C07D]

View all Patent…

  • No Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2017/0266,286 NOVEL PHARMACEUTICAL DOSAGE FORMS COMPRISING VALGANCICLOVIR HYDROCHLORIDE Abandoned Apr 05, 17 Sep 21, 17 [A61K]
2017/0114,146 Bispecific T cell activating antigen binding molecules Abandoned Sep 30, 16 Apr 27, 17 [C07K]
2017/0081,312 ANTIVIRAL COMPOUNDS Abandoned Dec 06, 16 Mar 23, 17 [C07D, A61K]
2017/0050,960 NEW BICYCLIC DERIVATIVES Abandoned Oct 12, 16 Feb 23, 17 [C07D]
2017/0037,121 FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES Abandoned Jul 14, 16 Feb 09, 17 [C07K]
2017/0037,153 FC-REGION VARIANTS WITH MODIFIED FCRN- AND MAINTAINED PROTEIN A-BINDING PROPERTIES Abandoned Jul 14, 16 Feb 09, 17 [C07K]
2017/0035,767 MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES Abandoned Oct 21, 16 Feb 09, 17 [A61K]
2017/0029,493 ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 Abandoned Apr 12, 16 Feb 02, 17 [C07K]
2017/0008,901 SPIRO-OXAZOLONES Abandoned Jun 06, 16 Jan 12, 17 [C07D]
2017/0008,949 Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure Abandoned Jun 09, 16 Jan 12, 17 [A61K, C07K]
2016/0369,234 CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) Abandoned Feb 18, 16 Dec 22, 16 [C12N, A61K]
2016/0333,386 USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXIGENASE (PAM) FOR C-TERMINAL AMIDATION Abandoned Jun 17, 16 Nov 17, 16 [C12P]
2016/0333,414 IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPY Abandoned May 22, 15 Nov 17, 16 [C12Q, A61K, G01N]
2016/0272,626 PYRAZINE DERIVATIVES Abandoned Nov 04, 13 Sep 22, 16 [C07D]
2016/0257,749 ANTI-TIM3 ANTIBODIES AND METHODS OF USE Abandoned Nov 06, 15 Sep 08, 16 [A61K, C07K]
2016/0256,529 COMBINATION THERAPY Abandoned Mar 07, 16 Sep 08, 16 [A61K]
2016/0251,621 SINGLE B-CELL CULTIVATION METHOD Abandoned May 06, 16 Sep 01, 16 [C12N, G01N]
2016/0220,669 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND TLR9 AGONIST Abandoned Oct 16, 15 Aug 04, 16 [A61K, C07K]
2016/0207,890 ETHYNYL DERIVATIVES Abandoned Mar 25, 16 Jul 21, 16 [C07D]
2016/0200,672 NEW PROCESS Abandoned Mar 22, 16 Jul 14, 16 [C07C]

View all Patent…

  • No Patents to Display

Top Inventors for This Owner

We are sorry but your current selection exceeds the maximum number of watches () for this membership level. Upgrade to our Level for up to watches!

Owner Watch
HOFFMANN-LA ROCHE INC.
CANCEL
UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to comparisons!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of portfolios () for this membership level. Upgrade to our Level for up to portfolios!

UPGRADE MEMBERSHIP CANCEL

We are sorry but your current selection exceeds the maximum number of patents allowed in portfolios () for this membership level. Upgrade to our Level for up to patents!

UPGRADE MEMBERSHIP CANCEL